BNB Plus Corp

bnbx.io

What Do They Do?

Manages a BNB-focused digital asset treasury and commercializes cell-free DNA and RNA production solutions for biopharmaceutical and diagnostics customers.

How Do They Make Money?

Customers pay for DNA products when they ship and for services when the work is complete. Product customers are invoiced at shipment; service customers are invoiced when the service is completed.

revenue

Segment	Share	Revenue	How money arrives
Product revenues Sold outright	67% FY2022: 10%		Sold outright
Service revenues Sold outright	33% FY2022: 4.2%		Sold outright

Who Are Their Customers?

Therapeutic DNA customers include biopharmaceutical and diagnostics companies. Products and services are sold directly to customers, and LineaRx also uses licensing and fee-for-service manufacturing arrangements.

Customers above 10% of revenue, FY2025

of revenue from three customers (20%, 10%, 29%)

FY2024: 28% from one customer

Do Revenues Turn Into Profits?

No. It lost $15.2M in FY2025.

Operating income, FY2025

−751% of revenue

▲ +17% (Loss) vs FY2024 (−$13.7M, −647%)

Net income, FY2025

−709% of revenue

▲ +117% (Loss) vs FY2024 (−$7M, −331%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q3 FY2026, the three months to Jun 30, 2026

Revenue: ▲ +99%; vs $304.4K in Q3 FY2025
Net income: ▲ +19% (Loss); vs −$3.9M in Q3 FY2025

Product revenues share of revenue vs 64.2% in Q3 FY2025

Jul 29, 2026 The company ended its digital asset and advisory agreements. The settlement included a $1,000,000 payment and the chairman’s resignation; the chief investment officer also left.
Jul 13, 2026 Nasdaq determined it would delist the company’s common stock. The company said trading would move to the OTCQB Venture Market while it sought review of the decision.

Shrinking. Revenue fell 76% in 4 years, from $9M in FY2021 to $2.1M in FY2025, about 30% a year.

Added a digital asset treasury The latest report adds a BNB-focused treasury strategy that seeks yield from digital assets. The older report describes a biotechnology business centered on synthetic DNA, testing services and DNA tagging.

Ended testing and industrial DNA activities The older report describes molecular diagnostic testing and DNA tagging alongside synthetic DNA production. The latest report says the company exited DNA tagging and stopped its clinical laboratory operations, leaving LineaRx as its nucleic acid production business.

Revenue over time

Product revenues Service revenues Clinical laboratory service revenues

$20M$10M$0

FY2021 FY2022 FY2023 FY2024 FY2025

Who Do They Compete With?

Competes with MilliporeSigma, Precigen, Aldevron, Integrated DNA Technologies, 4basebio, MaxCyte, Touchlight Genetics, Quantoom Bioscience, Syngoi Technologies, Novartis, OriGene Technologies, Blue Heron Biotech, Gene Art, GenScript Biotech, Elegen, ANSA Biotechnologies, Merck &, The Ether Machine, Sharplink Gaming, and Strategy

Comments